Spurious Drugs Case: Baddi Firm Owner Fails To Join Probe

Solan : Mukesh Saini, proprietor of Magnatek Enterprises, a pharmaceutical firm allegedly involved in the production of spurious drugs, failed to join the investigation at Baddi today.

The authorities sealed the unit on July 16 after seizing spurious drugs manufactured in violation of the Drugs and Cosmetics Act. The officials will inspect the premises in his presence.

CCTV footage obtained by drug officials showed him leaving the firm premises in a hurry around 8 pm on Sunday soon after a consignment was seized at the godown of a transport company.

He had reportedly received a call from the staff of the transport company about the seizure following which few other employees also made a hasty retreat on a bike while few lower-rung employees were left working in the unit.

Drugs Controller Navneet Marwaha said proprietor of Magnatek Enterprises Mukesh Saini failed to join the probe over the past two days. He has been granted the last opportunity tomorrow following which appropriate action would be taken against him.

With water-logging plaguing Delhi, the drug authorities are yet to verify whether a wholesale chemist in central Delhi had received any stock of spurious drugs manufactured at the Magnatek unit in the past.

Such a stock would be withdrawn from the market. The officials were verifying the other drug consignments sent by the firm to Chandigarh and other places.

It has been observed that wholesale traders from other states have direct links with the manufacturers at Baddi.

Related Posts

  • Pharma
  • June 23, 2025
  • 114 views
Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

LONDON:  Ananda Pharma PLC (AQSE:ANA, OTCQB: ANANF) has manufactured 40 liters of its lead investigational product MRX1 and 40 liters of matched placebo in compliance with pharmaceutical Good Manufacturing Practices…

  • Pharma
  • June 23, 2025
  • 141 views
Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Hyderabad:  In a ray of hope for HIV patients, particularly for the significant burden in the two-Telugu speaking States of Telangana and Andhra Pradesh, several India pharmaceutical companies have secured…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Drug licences of 9 pharma dealers suspended in Jammu

Drug licences of 9 pharma dealers suspended in Jammu

Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC

Sun Pharma Gets Relief on Packaging Norms for Pantoprazole-Levosulpiride FDC